What is the first‑line pharmacologic treatment for weight loss in an adult with BMI ≥30 kg/m² (or ≥27 kg/m² with obesity‑related comorbidities) who has no contraindications to GLP‑1 receptor agonists?

First-Line Weight Loss Medication

For adults with BMI ≥30 kg/m² (or ≥27 kg/m² with obesity-related comorbidities) who have no contraindications to GLP-1 receptor agonists, semaglutide 2.4 mg subcutaneous weekly is the first-line pharmacologic treatment, followed by tirzepatide as an equally effective alternative.

Evidence-Based Ranking

The most recent and highest-quality guidelines establish a clear hierarchy:

First-Line Agents (Tier 1)

• Semaglutide 2.4 mg subcutaneous weekly 1, 2

  • Achieves 14.9-16.0% total body weight loss at 68 weeks (vs. 2.4-5.7% placebo) 3
  • 69% of patients achieve ≥5% weight loss 4
  • Reduces cardiovascular events (HR 0.80; 95% CI 0.72-0.90) in patients with pre-existing CVD 3
  • Moderate-certainty evidence 2

• Tirzepatide 15 mg subcutaneous weekly 3, 2

  • Achieves 20.9% total body weight loss at 72 weeks (vs. 3.1% placebo) 3
  • Superior to semaglutide by 5.1% additional weight loss (95% CI 0.6-9.8%) 3
  • FDA approved November 2023 3
  • Moderate-certainty evidence 2

Second-Line Agent (Tier 2)

• Phentermine-topiramate ER 1, 2
  • Low-certainty evidence 2
  • Preferentially use in patients with comorbid migraines 1
  • Contraindicated in cardiovascular disease and uncontrolled hypertension 1
  • Requires monthly pregnancy tests; topiramate is teratogenic 1

Third-Line Agent (Tier 3)

• Liraglutide 3.0 mg subcutaneous daily 1, 2
  • Achieves 8.0% weight loss at 56 weeks (difference 5.4% vs. placebo) 3
  • Low-certainty evidence 2
  • May be preferred when cost/availability favors it over semaglutide 3

Fourth-Line Agent (Tier 4)

• Naltrexone-bupropion ER 1, 2
  • Low-certainty evidence 2
  • Consider for patients attempting smoking cessation or with depression 1
  • Contraindicated with seizure disorders and concurrent opiate use 1

Critical Implementation Points

Dosing Strategy

• Gradual titration is mandatory to mitigate gastrointestinal adverse effects (nausea 14-28%, vomiting 6-12%, diarrhea 8-20%) 4
• Start semaglutide at 0.25 mg weekly, escalate monthly to target 2.4 mg 3

Duration of Therapy

• Lifelong use is necessary for sustained benefit 3
• Weight regain occurs rapidly after discontinuation: 11.6% regain at 52 weeks post-cessation 3
• These are chronic disease medications, not short-term interventions 1

Monitoring Requirements

• GLP-1 RAs: Monitor for pancreatitis and gallbladder disease 1
• Phentermine-containing agents: Monitor blood pressure and heart rate periodically 1
• Naltrexone-bupropion: Monitor blood pressure/heart rate especially first 12 weeks; assess for suicidal ideation 1, 2

Common Pitfalls to Avoid

1. Do not use phentermine or diethylpropion monotherapy beyond 12 weeks without recognizing this is off-label 1
2. Do not prescribe phentermine-topiramate to women of childbearing potential without effective contraception and monthly pregnancy testing 1
3. Do not stop medication after achieving weight loss goal—this guarantees weight regain 3
4. Do not use compounded GLP-1 formulations—only FDA-approved products are recommended 5

Special Populations

With Type 2 Diabetes

• Semaglutide and tirzepatide provide dual benefit: weight loss plus glycemic control 3, 1, 6
• Tirzepatide achieves 9.5 kg weight loss at 40 weeks in diabetic patients 4

With Cardiovascular Disease

• Semaglutide is preferred due to proven CV risk reduction 3
• Avoid phentermine-topiramate entirely in this population 1

Cost/Access Barriers

• When GLP-1 RAs are unavailable, liraglutide may serve as cost-effective alternative 4
• Selection must balance clinical profile, comorbidities, and patient preferences 1, 2